Herriot Tabuteau and Axsome Therapeutics Overview
Herriot Tabuteau is a former executive at Axsome Therapeutics, a clinical-stage biopharmaceutical company focused on central nervous system disorders. Axsome trades on the NYSE under the ticker AXSM, with its stock price, market capitalization, and pipeline data publicly reported through financial data platforms and company filings AXSM stock data on Nasdaq. Public filings and business profiles describe Tabuteau as a former Chief Financial Officer and Senior Vice President at Axsome, with prior roles at other biopharma and investment firms.
Axsome Therapeutics was founded in 2019 and went public through a merger with a special purpose acquisition company, with its shares listed on the New York Stock Exchange. The company's pipeline includes investigational treatments for major depressive disorder, schizophrenia, and other CNS indications. Tabuteau's tenure at Axsome coincided with key clinical-stage milestones and public disclosures about the company's financial position and capital raises.
Herriot Tabuteau's Career and Financial Roles
Professional Background
Before Axsome, Herriot Tabuteau held positions at investment and financial institutions, with public records linking him to roles involving corporate finance, strategic transactions, and capital markets activities. His profile appears in business databases and SEC filings associated with public companies and SPAC structures.
At Axsome Therapeutics, Tabuteau served as Chief Financial Officer and Senior Vice President, overseeing financial reporting, investor relations, and corporate strategy during a period of active clinical development. His responsibilities included managing capital raises, balance sheet positioning, and communication with shareholders and analysts, as reflected in public company filings and press releases Axsome Therapeutics SEC filings.
Axsome Therapeutics: Market Position and Public Data
Stock and Financial Metrics
Axsome Therapeutics' market capitalization, share price, and trading volume are tracked by major financial data providers, with real-time quotes and historical performance available through brokerage platforms and financial news sites. The company's financial results are disclosed in quarterly and annual reports filed with the U.S. Securities and Exchange Commission.
Investors and analysts follow Axsome for its pipeline progress in CNS therapeutics, with updates on clinical trial readouts, regulatory interactions, and partnership announcements. Public information about the company's executives, including Herriot Tabuteau, is accessible through corporate governance disclosures and proxy statements Forbes guide to reading proxy statements.